Johnson & Johnson’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.5M Hold
814,586
– – 2.95% 6
2026
Q1
$14.7M Hold
814,586
– – 2.26% 7
2025
Q4
$17.7M Hold
814,586
– – 3.19% 7
2025
Q3
$26.6M Hold
814,586
– – 5.27% 6
2025
Q2
$28.2M Hold
814,586
– – 8.44% 4
2025
Q1
$27.6M Hold
814,586
– – 8.08% 4
2024
Q4
$26.5M Hold
814,586
– – 6.86% 7
2024
Q3
$39.7M Hold
814,586
– – 9.29% 3
2024
Q2
$36.1M Hold
814,586
– – 9% 4
2024
Q1
$45.7M Hold
814,586
– – 1.04% 6
2023
Q4
$49M Hold
814,586
– – 1.12% 4
2023
Q3
$54.7M Hold
814,586
– – 20.16% 1
2023
Q2
$56.2M Sell
814,586
-814,587
-50% -$53.2M 17.46% 2
2023
Q1
$78.6M Hold
1,629,173
– – 25.55% 1
2022
Q4
$81.3M Hold
1,629,173
– – 23.66% 1
2022
Q3
$66.5M Hold
1,629,173
– – 19.56% 2
2022
Q2
$89.6M Hold
1,629,173
– – 22.89% 1
2022
Q1
$59.2M Hold
1,629,173
– – 11.19% 2
2021
Q4
$75.9M Hold
1,629,173
– – 8.64% 4
2021
Q3
$82.4M Buy
+1,629,173
New +$67.8M 7.23% 4

Other funds holding LEGN

Johnson & Johnson's LEGN Position: Q2 2026 in Review

Johnson & Johnson held its Legend Biotech (LEGN) position steady in Q2 2026 at 814,586 shares worth $23.5M. The position accounts for 2.95% of the portfolio, ranked #6.

Johnson & Johnson first reported a position in LEGN in Q3 2021 and has held it in 20 quarters since. The position peaked at $89.6M in Q2 2022. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Johnson & Johnson held 814,586 shares of Legend Biotech worth $23.5M as of Q2 2026.
  • Johnson & Johnson left its Legend Biotech share count unchanged in Q2 2026.
  • Legend Biotech made up 2.95% of Johnson & Johnson's portfolio in Q2 2026, its #6 holding.
  • Johnson & Johnson first reported a position in Legend Biotech in Q3 2021 and has held it in 20 quarters since.
  • Johnson & Johnson's Legend Biotech position peaked at $89.6M in Q2 2022.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.